Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 21.8% in the fourth quarter, according to the company in its most ...

Needham & Company LLC reiterated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report released on Friday,Benzinga reports. Several other equities ...

UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118 ...

Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

Shares of Neurocrine Biosciences Inc. plummeted 19 percent week-on-week to close Friday’s trading at $122.62 each as ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price ...